Few facts about COVID-19 vaccine development- Where are we w
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Worldwide researchers are racing to develop a vaccine against SARS-CoV-2, the virus that causes COVID-19, which has brought the world to a social and economic standstill. Hundreds of institutions and individuals in academic, biotechnology, government, and pharmaceuticals - embarked on one of the most consequential scientific endeavors in living memory.

Here are few facts about vaccine development:

1. Vaccine developers and government officials are publicly reporting timelines for emergency use of vaccine candidates between the 4th quarter of 2020 and the 1st quarter of 2021.

2. The early data on vaccine safety and immunogenicity in Phase I and II trials are promising—although in a limited number of subjects to date.

3. The discrete characteristics of the virus, the sheer number of development efforts, and innovators’ unprecedented access to funding all provide reasons to believe that a COVID-19 vaccine can be developed faster than any other vaccine in history.

4. Vaccine manufacturers have announced cumulative capacity that could produce as many as one billion doses by the end of 2020 and nine billion doses by the end of 2021. Taken together, all the evidence suggests that COVID-19 vaccines are likely to become available for focused populations somewhere around the first quarter of 2021.

Vaccine Development in India:

In November, Bharat Biotech announced India’s first indigenous Covid-19 vaccine candidate, Covaxin. The vaccine has already been evaluated in 1000 subjects in phase I and phase II clinical trials and has shown promising safety and immunogenicity data. The trial will involve 25,000 volunteers over 18 years of age across 25 centres in the country and is taken up in partnership with ICMR.

The timing question is becoming a bit clearer, as is the question of how much value may be created by the global launch of successful vaccines against COVID-19. Based on the established set of facts, experts agree a vaccine for COVID-19 is likely to be available somewhere between the fourth quarter of 2020 and first quarter of 2021, most likely for use in specific populations, with additional candidates coming on line by the end of 2021.

Source: http://sfa3.mankindpharma.in/wsfaapi/doc/Where_are_we_with_COVID-19_vaccine_converted.pdf
Dr. C●●●●g R●●●●●i and 1 others like this